Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.

被引：0
|
作者：
Xu, Chongrui
Tu, Hai-Yan
Sun, Yue-Li
Li, Yang-Si
Xu, Bing-Fei
Wang, Bin-Chao
Chen, Hua-Jun
Wang, Zhen
Zhou, Qing
Yang, Jin-Ji
Wu, Yi-Long
机构：
[1] South China Univ Technol, Sch Med, Guangdong Acad Med Sci, Guangdong Lung Canc Inst,Guangdong Prov Peoples H, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21670
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Perioperative Nivolumab in non-small cell Lung Cancer
    Lorenz, Judith
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (18) : 1065 - 1066
  • [42] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.
    Park, Keunchil
    Cho, Eun Kyung
    Kang, Jin Hyoung
    Han, Ji-Youn
    Lee, Jong Seok
    Kim, Dong-Wan
    Kim, Sang-We
    Cho, Byoung Chul
    Min, Young Joo
    Lee, Ki Hyeong
    Kim, Joo-Hang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [43] Carcinoembryonic antigen-positive pleural effusion in early stage non-small cell lung cancer without pleural infiltration
    Enz, Njanja
    Fragoso, Fernando
    Gamrekeli, Alexander
    Lippek, Frank
    Jungraithmayr, Wolfgang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (05) : E340 - E343
  • [44] Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer
    Kataoka, Yuki
    Hirano, Katsuya
    Narabayashi, Tomoko
    Hara, Satoshi
    Fujimoto, Daichi
    Tanaka, Tae
    Ebi, Noriyuki
    Tomii, Keisuke
    Yoshioka, Hiroshige
    ANTICANCER RESEARCH, 2018, 38 (01) : 559 - 563
  • [45] Renal transplantation in Hepatitis B surface antigen-positive (HBsAg) patients. Consequence of use HBsAg positive donors.
    Segura, J
    Andres, A
    Herrero, JC
    Morales, JM
    Morales, E
    Roca, A
    Alegre, R
    Praga, M
    Rodicio, JL
    KIDNEY INTERNATIONAL, 1999, 55 (01) : 376 - 376
  • [46] Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Zullo, L.
    Cella, E.
    Paoloni, F.
    Gualtieri, M.
    Barletta, G.
    Favero, D.
    Parisi, F.
    Dellepiane, C.
    Rossi, G.
    Bennicelli, E.
    Zinoli, L.
    Cantini, L.
    Pecci, F.
    Del Mastro, L.
    Berardi, R.
    Genova, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S78 - S79
  • [47] Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
    Kanai, Osamu
    Kim, Young Hak
    Demura, Yoshiki
    Kanai, Makiko
    Ito, Tsuyoshi
    Fujita, Kohei
    Yoshida, Hironori
    Akai, Masaya
    Mio, Tadashi
    Hirai, Toyohiro
    THORACIC CANCER, 2018, 9 (07) : 847 - 855
  • [48] Outcomes of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) in A Regional Australian Population
    Kasherman, Lawrence
    Brungs, Daniel
    Bell, Graeme
    Glasgow, Amanda L.
    Tafreshi, Ali
    Clingan, Philip
    Aghmesheh, Morteza
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 145 - 146
  • [49] Physiological correlates of cancer-related fatigue in advanced non-small cell lung cancer (NSCLC) patients.
    Swanson, T.
    Dalzell, M. A.
    Small, D.
    MacDonald, N.
    Kreisman, H.
    St-Pierre, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 474S - 474S
  • [50] Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer with Preexisting Interstitial Lung Disease
    Kanai, O.
    Kim, Y.
    Demura, Y.
    Kanai, M.
    Fujita, K.
    Yoshida, H.
    Akai, M.
    Mio, T.
    Hirai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2420 - S2420
12345